Results 111 to 120 of about 180,829 (383)
Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
Cells, 2018 Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects in reduction of disease activity in multiple sclerosis (MS) patients and has recently been approved for the treatment of patients with relapsing MS (RMS) and primary ...
Stefan Gingele +14 more
doaj +1 more source
Memory NK cell features exploitable in anticancer immunotherapy [PDF]
, 2019 Besides their innate ability to rapidly produce effector cytokines and kill virus-infected or transformed cells, natural killer (NK) cells display a strong capability to adapt to environmental modifications and to differentiate into long-lived ...
Battella, Simone +5 more
core +2 more sources
CD20 as a gatekeeper of the resting state of human B cells
Proceedings of the National Academy of Sciences of the United States of America, 2020 Significance Worldwide about one million patients are given anti-CD20 antibodies such as rituximab (RTX) for the treatment of B cell-associated diseases.
Kathrin Kläsener +12 more
semanticscholar +1 more source
Cancers, 2021 Simple Summary The complex interplay between the different cellular components in the tumor microenvironment (TME) dynamically modulates the antitumor immune response.
F. J. Suárez-Sánchez +8 more
semanticscholar +1 more source
Advanced Healthcare Materials, EarlyView.Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez +4 more
wiley +1 more source
HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies [PDF]
Blood, 2017 Key Points HDAC6 inhibition represents a novel strategy to improve the efficacy of anti-CD20 mAbs. HDAC6 inhibition increases CD20 levels by enhancing CD20 protein synthesis without affecting the gene expression.
Bobrowicz, Malgorzata +32 more
openaire +2 more sources
Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients [PDF]
, 2015 Natural Killer (NK) cells are a key component of tumor immunosurveillance and thus play an important role in rituximab-dependent killing of lymphoma cells via an antibody-dependent cellular cytotoxicity (ADCC) mechanism.
Battella, Simone +13 more
core +1 more source
Kidney International, 2020 B-cell depletion with anti-CD20 monoclonal antibodies is widely used for the treatment of autoimmune diseases. This review will discuss mechanisms contributing to success or failure of B-cell depletion therapy in antibody-mediated autoimmune diseases. It
Étienne Crickx +3 more
semanticscholar +1 more source
Advanced Science, EarlyView.This study demonstrates that Mn2⁺–tumor DNA complexes encapsulated in dendritic cell (DC)– derived immunogenic extracellular vesicles (EVDC@Mn‐DNA) act as a DC‐specific cGAS– STING activator. EVDC@Mn‐DNA treatment enhances intratumoral DC activation, improves tumor vascular function, promotes CD8⁺ T cell activity, and suppresses pancreatic tumor growth,
Xue Jiang +13 more
wiley +1 more source
Adaptive immunity in cancer immunology and therapeutics. [PDF]
, 2014 Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Lockley, M, Spurrell, EL
core +2 more sources